Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-01-18

Clinical Trial Update: Urticaria Facticia Treatment With Omalizumab (UFO) [Phase 2]

View source ↗

Summary

Phase 2 trial update of omalizumab for urticaria symptoms (symptomatic dermographism) completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Omalizumab (Omalizumab)

Snippet

Sponsor: Charite University, Berlin, Germany | Conditions: Symptomatic Dermographism | Phase 2 | Status: COMPLETED | Results posted: 2016-01-18